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Abstract
Background: The state of oligomerization of surfactant associated protein-A (SP-A) monomers differs between individuals.
This likely affects SP-A’s functional properties and could thereby influence clinical status in patients with lung diseases. In
this study we focus on SP-A structure in cystic fibrosis (CF) compared to both healthy subjects and disease controls.
Methods: SP-A composition and function were assessed in both bronchoalveolar lavage (BAL) fluid and serum of 46 CF
patients with mild disease, 25 patients with chronic bronchitis and 22 healthy subjects by gel chromatography and
a functional agglutination assay. Relation of SP-A agglutination ability to disease severity of the subjects was explored.
Results: SP-A was present in seven major oligomeric forms with the majority of SP-A being structurally organized as
complex oligomeric forms. More complex oligomeric forms were associated with better SP-A function with regard to its
agglutination ability. These forms were more frequently observed in BAL than in serum, but there were no differences
between disease groups. In CF patients, more complex forms of SP-A were associated with better lung function.
Conclusions: Organizational structure of SP-A affects its functional activity and is linked to disease severity in CF.
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Introduction
Surfactant associated protein-A (SP-A) is the most abundant
pulmonary surfactant protein and belongs to the family of innate
host defense proteins termed collectins. SP-A is involved in
surfactant metabolism and recognizes pathogen-associated molec-
ular patterns on microorganisms, resulting in aggregation,
opsonization or permeabilization of microorganisms and facilita-
tion of microbial clearance [1]. Intermolecular disulfide bonds at
the N-terminal end enable the aggregation of trimers to higher
oligomers, whereas the neck region arranges the trimer association
of the globular domain and influences the binding to phospho-
lipids and bacterial lipid A. Functional properties of SP-A may
depend on its supratrimeric assembly and organization [2–4].
While the relevance of the higher-order oligomerization of lung
collectins for their functional capabilities has been extensively
studied for SP-D [5], little data is available for SP-A multimers
[4,6,7].
Cystic fibrosis (CF) is a life limiting disease associated with
chronic pulmonary infections [8]. Bronchoalveolar lavage (BAL)
levels of SP-A have been shown to be increased early in the course
of the disease [9], but decrease as disease progresses and lower
levels are correlated with more inflammation and diminished lung
function [10–15]. Currently, there are no data available on
macromolecular organization of SP-A in BAL and its potential
functional role in CF airway disease.
The aims for this study were to assess structural organization in
CF compared to other airway diseases and controls, relate
organization to functional activity in vitro, and to explore
associations between SP-A organization and function with clinical
markers of disease severity in CF patients.
Methods
Ethics Statement
The study was approved by the institutional review board, the
Ethics committee of the Medical Faculty of the LMU Munich (EK
026-06) and all participants gave their written informed consent.
Subjects
46 patients with CF, 25 patients with chronic bronchitis and 22
healthy control subjects (controls) were included in this study.
Samples were collected in previous studies [13,16,17] and details
of the patients are given in Table 1. We preferentially studied these
only mildly affected patients in order to avoid secondary
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alterations caused by severe neutrophilic airway inflammation.
Pulmonary disease severity was assessed according to Schluchter et
al 2006 who used the mean change of FEV1 per year (DFEV1)(%
pred.), allocation to lung disease severity group (mild/moderate/
severe; i.e. mild, if FEV1 % pred. at the age of 20 years $ 84,
severe, if #54) and the FEV1 at the age of twenty (FEV1 (%
pred.)age 20), which was calculated from all FEV1 (% pred.)
available and covered an average of at least 3 years before the
latest sampling point with four values each year per patient [18].
BAL
BAL was performed with 461 ml/kg body weight normal saline
warmed to body temperature [13]. The first aliquot of the
recovered BAL fluid was treated separately; all other samples were
pooled and used for analysis in this study.
Gel Chromatography
To determine the structural organization of SP-A in BAL and
serum gel chromatography on a superpose 6 column was used as
described in previous studies [6,7]. This method separates SP-A
molecules with regard to their oligomerization form. The column
was calibrated by using blue dextran (2000 kDa), holotransferrin
(669 kDa) and bovine serum albumin (66 kDa)(not shown).
Samples of 1 ml of BAL fluid and 500 ml of serum were loaded.
The SP-A content of the eluted fractions (800 ml) was determined
by Slot-Blot assay. The void volume of the column eluting between
fractions 8 and 9 was about 6.8 ml. SP-A usually elutes as three
distinct peaks, ranging from fractions 9–12, 13–17 and 18–22
(Fig. 1). The first peak contains the largest SP-A multimers, i.e.
18 mers and bigger, the second peak 6 to 12 mers and the third
peak di- and trimers. A major peak was defined to be present if the
SP-A amount was at least or more than 20 % of the total SP-A
eluted from the column and each peak was separated from the
previous by a distance of 5 fractions of 0.8 ml each. The cut off of
20% was arbitrarily selected after visual inspection of all
chromatograms normalized into a grid. There were baseline
fluctuations and drifts up to 10% and the level of 20% of total SP-
A was selected to define the presence or absence of a peak in the
preset elution fractions. There were a total of 140 chromatograms
which had a potential for 177 changes in pattern (i.e. 010 can
improve or deteriorate, etc). Lowering the threshold to 10%,
would introduce 15 changes in the category of the pattern in both
directions and a net change of 5 improvements. The threshold set
also makes sure that a peak is represented by a sufficient amount of
the total SP-A.
Depending on the presence (1) or absence (0) of any of the three
major peaks in a sample (Fig. 1), generally 7 different patterns of
SP-A can be classified (‘‘Code’’ in first column of Table 2). The
inter-run reproducibility of the separation of SP-A by the gel
chromatography and determination of SP-A concentration by slot-
blot was assessed in four serum and 2 BAL samples of 5 different
individuals by repeated analysis at intervals of four weeks. The
reproducibility of the gel chromatography was excellent compar-
ing the curve forms, the coefficient of variation for SP-A content
assessed by the area under the curve of the peaks was 29%.
SP-A present in each of the fractions from gel chromatography
was determined by slot blot (see below) and the amounts of the
different structures were calculated from the area under the curve
of the corresponding peak as a percentage of total amounts of SP-
A present (Fig. 1).
Table 1. Clinical data of the subjects investigated.
Subjects’ characteristics Cystic fibrosis Chronic bronchitis Controls
Age (years) 1366 (n = 46) 11612 ( n = 25) 1669 ( n = 22)
Gender in % female (absolute numbers)) 57 (26) 52 (13) 36 (8)
Body mass index in % overweight/normal/underweight (absolute
numbers)1
20/47/33 (7/22/15) 17/83/0 (2/10/0) 0/100/0 (0/19/0)
FEV1 (% pred.)11 94626 (n = 46) 94622 (n = 8) 118 (n = 1)
Mean change of FEV1 per year (DFEV1)(% pred.)111 –3610 (n = 42) n.k. n.k.
Lung disease group in % mild/moderate/severe (absolute numbers) 72/0/28 (28/0/11) 91/9/0 (10/1/0) 100/0/0 (22/0/0)
P.aer. infection of the lung at sampling point (%) 24 (n = 11) n.k. n.k.
IgG in serum (ratio to upper normal value) 0.961.8 (n = 28) 0.560.4 (n = 10) n.k.
Neutrophils in BAL (%) 28622 (n = 39)** 766 (n = 11) 262 (7)
SP-A level in BAL (ng/ml)1111 502363314 (n = 39) 769866323 (n = 13) 620465111 (n = 8)
SP-A level in serum (ng/ml)1111 2669 (n = 37) 36614 (n = 6) 26611 (n = 15)
Agglutinate size in BAL (Pixel) (18mers/6mers/trimers) 316630/234615/74615
(n = 10)
370643/316619/114613
(n = 10)
517634/352612/11867
(n = 10)
Agglutinate size in serum (Pixel) (18mers/6mers/trimers) 481635/380632/146613
(n = 10)
469636/377618/14368
(n = 10)
525631/361615/13267
(n = 10)
Data are mean 6 SEM of n subjects or the percentage of subjects in a group (in brackets absolute number of subjects). Statistical comparisons were made by One-way
ANOVA with post hoc test, Tukey ** indicates a significant difference (p,0.01) compared to chronic bronchitis and controls.
n.k.: not known.
1BMI = body mass index (weight (kg)/(length (m2)). Age-dependent cut-off values used to define weight status groups (underweight, normal, overweight) were taken
from the global database on body mass index (http://www.who.int/bmi/index.html).
11indicates FEV1 (% pred.)age 20 for patients with cystic fibrosis, calculated according to Schluchter et al 2006,
111data were calculated from all mean FEV1 (% pred.) available and covered an average of at least 3 years before the latest sampling point with four values each year per
patient.
1111Serum and lavage samples were not available as pairs in all subjects; thus the numbers of each measurement are different.
There was no correlation between the neutrophils in BAL (%) or the IgG in serum (ratio to upper normal value) and the FEV1 (% pred.).
doi:10.1371/journal.pone.0051050.t001
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Slot Blot and SP-A Self-agglutination Measurement
The SP-A concentration of chromatography fractions was
determined by the slot-blot method. An assay previously designed
to assess the ability of SP-A in serum and BAL samples to
agglutinate, was used [19]. Briefly, anti-SP-A antibodies (poly-
clonal recombinant rabbit-anti-human SP-A antibody (Nycomed,
Konstanz, Germany) which bind SP-A at its N-terminal end were
coupled to 0.05 mm latex beads, so that the bound SP-A was able
to interact by its C-terminal CRD with other SP-A molecules in
a given sample. This causes agglutination of the beads forming
larger aggregates, which were observed by light microscopy. The
agglutinates were photographed at 10 fold magnification, the
pictures viewed with Adobe Photoshop software and the size of all
the agglutinates (typically more than 100) was assessed and the
largest measured in pixels by drawing squares around them and
averaged by a blinded examiner with regard to the diagnosis [19].
Results
Clinical characteristics of the study population are shown in
Table 1. CF patients included in this study had mild lung disease
as indicated by a normal mean FEV1 and the majority had
a normal nutritional status expressed as BMI. The rate of P.
aeruginosa positive cultures was low and mean serum IgG,
a marker of the systemic inflammatory response, was within the
normal range. In contrast to the controls and the subjects with
chronic bronchitis, the CF patients had moderately increased
neutrophilic counts (Table 1). The total levels of SP-A in serum or
BAL were not different between the patients with CF and those
with bronchitis and the controls (Table 1).
In BAL there were no differences in the oligomeric distribution
of SP-A between the 3 study populations (Table 2). Complex
oligomeric forms of SP-A such as octadecamers (first peak) were
the most prevalent form (85% of all subjects), followed by smaller
oligomeric forms such as hexamers (54% of all subjects, second
peak), and dimers or trimers (52% of all subjects, third peak).
In serum, all controls showed dimers and trimers, smaller and
larger oligomeric forms were observed at a lower rate. In-
terestingly, octadecamers (present above the threshold defined at
20% of the SP-A in a sample) were infrequently identified in sera
of control patients (Tables 1 and 2).
No correlation in oligomer pattern between corresponding
serum and bronchoalveolar lavage samples was observed, regard-
less of whether the overall pattern (Tab. 2) or individual peaks
were considered (data not shown).
As expected in CF patients neutrophils and elastase activity
were elevated in CF BAL fluid (36638 U/ml, n= 18, compared to
normal reference where there is no free elastolytic activity [20,21].
However, not all patients had activity in their BAL and there was
only a weak (P,0.05, r = 0.478) correlation between elastase and
SP-A present as dimers/trimers (%), but not to the higher
oligomeric forms or the pattern frequencies. No correlations were
found with the neutrophils (%).To assess the relationship between
oligomeric organization of SP-A and its function in CF patients,
a functional rank order regarding organizational structure ranging
from more to less complex structure was generated
(001,010,011,111,110,101,100). As shown in Fig. 2 a+b
more of the complex forms were associated with larger
agglutinates. To analyze whether these correlations were caused
by structural composition of the whole samples, or the composition
of an individual fraction of a sample, individual fractions were
isolated from patients’ samples and analyzed at equal SP-A
concentrations for their ability to agglutinate. No differences in
agglutination activity were observed for the same oligomeric
forms, isolated from subjects with different oligomeric pattern
(data not shown). This suggested that rather than potential
differences among the oligomeric forms within a particular
fraction, the relative composition of different oligomeric forms in
a given sample is responsible for its activity.
To assess the relationship between organizational structure of
SP-A, and clinical markers of disease severity, we assessed its link
to FEV1; an important surrogate for the course of lung disease and
survival. Mean FEV1 (% pred.)age20 was higher in patients with the
‘‘100’’ form, compared to those with more SP-A present as less
complex forms (Fig. 2 c, d). This association was seen both in BAL
Figure 1. Illustration of the column characteristics for the separation of SP-A present in bronchoalveolar lavage or serum samples.
Samples from different patients were run on the column and SP-A content of each fraction was determined and plotted, normalized to its total
amount eluting from the column. Here, selected samples from three different subjects, each with a distinct extreme pattern of elution, are shown
(patient A (squares), having mainly one initial peak around fraction 10 contains 18-mers and larger; patient B (triangles), having mainly a peak around
fraction 15 with SP-A 6–12-mers; and patient C (circles), having mainly the lower molecular weight forms of SP-A).
doi:10.1371/journal.pone.0051050.g001
Supratrimeric SP-A and Pulmonary Outcome in CF
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and serum. In addition, the size of the agglutinates was positively
correlated to lung function (see Fig. 3 a–d).
Discussion
Structural Diversity of SP-A Oligomeric Organization
The majority of SP-A in BAL of both healthy people and CF
patients with mild lung disease is structurally organized as complex
oligomeric forms. This result is similar to that we have obtained
previously in healthy controls and patients with gastro-esophageal
reflux disease [6]. The seven major oligomeric patterns of SP-A
separated by gel chromatography were also not different between
the patients groups studied, but were linked to disease severity in
CF suggesting that more complex SP-A organization is linked to
better clinical status.
For the first time we determined the SP-A oligomeric pattern in
serum, in order to have a more convenient way of assessment than
BAL. In serum multimeric forms were less frequently observed
than in BAL (Table 2). Interestingly in serum, multimeric forms
were present (above the lower level of 20% of total SP-) in about
70% of CF patients and 50% of bronchitis. As multimeric forms of
SP-A are more active, we speculate that in CF and in part in
bronchitis they may result from disease-induced systemic activa-
tion and enhanced formation. The lack of correlation between
serum and lavage compartments may reflect no direct feed of the
serum compartment from the alveolar space [22,23].
SP-A Oligomeric Structure and Function are Inter-
connected in Humans and Superior Functional Activity is
Linked to Better Course of Lung Function
The capacity of SP-A from serum and BAL to induce
agglutination was linked to the organizational structure of
naturally occurring macromolecular forms. The more complex
the oligomeric forms were the better was SP-A dependent
agglutination. The rank order was the same in BAL and serum.
There are no in vitro data available which rank different oligomeric
structures of SP-A with regard to interaction with micro-
organisms, however results from studies with a mix of SPA1/SP-
A2 and with SP-A2 which have a higher degree of oligomerization
than SP-A1 demonstrate a better binding and aggregation of
Figure 2. Relationship between different structure compositions of SP-A and their agglutination ability (A,B) as well as their
association with lung function (C,D). The graphs illustrate the agglutination ability differences between different oligomeric structure
compositions (forms) in BAL (A) and serum (B) analyzed by gel chromatography. 42 BAL samples and 31 serum samples of CF patients were analyzed.
In serum only the 010 and 110 forms showed a significant difference regarding the agglutination ability compared to other forms. In BAL the 100
form agglutinated significantly better than the 111, 110 and 101 form and the 101 form significantly better than the 111 and 101 form. The graphs
(C,D) plot the relation between the lung function (y-axis) and the oligomeric SP-A distribution in BAL (C) and in serum (D). For analysis One way
ANOVA with Tukey as post-test was used and in all cases with a significant result (P,0.05), post hoc tests were calculated. Differences between
groups are indicated by dotted (P,0.05) or solid (P,0.01) lines.
doi:10.1371/journal.pone.0051050.g002
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bacterial lipopolysaccharides by the more complex macromolec-
ular forms of SP-A [4]. In studies utilizing SP-A derived from
patients with alveolar proteinosis, which also has a macro-
molecular organization as larger oligomers, the phagocytosis of
Staphylococcus aureus by monocytes was enhanced by binding to
C1qR [24]. Similarly, Pseudomonas aeruginosa and A. fumigatus
agglutination, uptake and killing by phagocytic cells were superior
[25–27].
Factors that may Influence SP-A Oligomeric Composition
On the level of the protein, an important factor which may
determine amount and structural organization of SP-A is the
overall proteolytic activity present in alveolar lining fluid [6,12]. In
the present study we compared three patient groups, including
mild CF patients with a normal lung function. In this group of CF
patients neutrophils and elastase activity in BAL were elevated,
although to a small extent. As expected on the basis of previous
data [19], the functional activity of SP-A for agglutination, i.e. the
size of agglutinates formed (Table 1) was reduced in CF patients.
However the structural organization was not different to the
comparison groups. This suggests that changes in the structural
organization pattern of the SP-A may be much less sensitive to
proteolytic activity than SP-A function. Thus the differences in
functional activity of SP-A between the three groups in face of
unchanged structural organization pattern may have been
primarily the result of proteolysis of SP-A within multimers.
In CF patients, there was only a very weak direct correlation of
elastase activity to the SP-A present as dimers/trimers (%), and
none to higher oligomers. Clearly, the oligomeric pattern of SP-A
present on itself was a considerably stronger determinant of its
agglutination activity and was consistently linked to lung function.
This observation is in agreement with results showing that the
complex oligomerization of SP-A was essential for the collagen
triple helix stability, protection against proteases, and SP-A-
induced ligand aggregation [4]. Oligomeric pattern of SP-A may
represent an additional factor of resilience to protect from loss of
lung function.
The observed complexity of SP-As structural organization is
likely based on the complex genetic organization of SP-A. Due to
the presence of 2 SP-A genes, SFTPA1 and SFTPA2, in which
more than 130 single nucleotide polymorphisms have been
detected within the coding region, the resulting in a number of
Figure 3. Correlation between agglutinate size and FEV1 (% pred.)age20 and DFEV1 (% pred.)/year. The graphs show on the x-axis the
SP-A agglutination size in whole, non-size fractionated BAL (A, C) and serum (B, D) in Pixel and in the y-axis the FEV1 (% pred.)age20 (A, B), and
accordingly DFEV1 (% pred.)/year (C, D). 28 BAL samples and 12 serum samples of CF patients were used for the graphs a and b and 26 BAL samples
and 14 serum samples of CF patients could be included in the graphs C and D. The p-values analyzed by linear regression were 0.0076 (r2 = 0.2438) for
BAL (A) and 0.0417 (r2 = 0.2819) for serum (B) as well as 0.0147 (r2 = 0.2156) for BAL (C) and 0.0343 (r2 = 0.3006) for serum (D).
doi:10.1371/journal.pone.0051050.g003
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allelic variants is large [28,29]. Additionally, many mRNA splice
variants at variable stability and expression levels add to
a significant number of peptides generated by one of the many
haplotypes to be combined in the final SP-A multimer. For the
analysis of associations between genetic SP-A variants and
variation of SP-A protein concentrations and functional properties
larger numbers of samples than investigated in this cohort are
clearly necessary.
This study has some limitations. Although we investigated
a rather large population with complex biochemical investigations,
due to the significant number of different naturally occurring
structural organizational forms of SP-A, the desirable number of
subjects in some of the groups were lower than anticipated.
Additional factors, like the atopy status, as suggested by Hickling et
al. who found a higher percentage of complex oligomers like
octadecamers in BAL from healthy persons compared to BAL
from birch pollen from 11 allergic persons [7] may play an as yet
undetermined role in influencing SP-A oligomeric composition.
Lastly, more information on the generation and metabolism as
well as in vivo function of the complex oligomeric forms may be
helpful to explain the intriguing observations made in this study.
We selected to assess the multimeric state of SP-A by using
Latex beads instead of bacteria, as the results can be better
generalized and are more reproducible be obtained for several
reasons; (1) not all bacterial strains behave in the same way, even
within a species (e.g. [26,30]) wide variation in agglutination is
observed; (2) agglutination may be depended on the growth phase
of the bacterial strain (own unpublished observation), and (3) the
assay used has been investigated extensively previously in a pre-
vious study [19], allowing others to reproduce the findings
independently. In addition, the purpose of the assay is to
demonstrate the multi-valence of SP-A and compare it between
subjects and not so much to assess different micro-organisms.
Lastly, if bacteria would have been used, additional factors present
in BAL or serum and interacting with other receptors on the
bacterial surface might have interfered with such an assay.
In summary, our results demonstrate the presence of a wide
range of naturally existing forms of SP-A oligomers, which are of
functional relevance in patients with chronic lung diseases like
cystic fibrosis. Such a close link between SP-A structure, its
agglutination activity and patients lung function, underline the role
of SP-A for human lung health.
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